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Systemic lupus erythematosus (SLE; OMIM 152700) is a genetically complex 
autoimmune disease characterized by loss of immune tolerance to nuclear and cell 
surface antigens.  Previous genome-wide association studies (GWAS) had modest 
sample sizes, reducing their scope and reliability.  Our study comprised 7,219 cases 
and 15,991 controls of European ancestry: a new GWAS, meta-analysis with a 
published GWAS and a replication study.  We have mapped 43 susceptibility loci, 
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including 10 novel associations.  Assisted by dense genome coverage, imputation 
provided evidence for missense variants underpinning associations in eight genes.  
Other likely causal genes were established by examining associated alleles for cis-
acting eQTL effects in a range of ex vivo immune cells.  We found an over-
representation (n=16) of transcription factors among SLE susceptibility genes.  This 
supports the view that aberrantly regulated gene expression networks in multiple cell 
types in both the innate and adaptive immune response contribute to the risk of 
developing SLE. 
SLE is a clinically heterogeneous disease with a strong genetic component, as 
demonstrated by the tenfold increase in concordance rates between monozygotic and 
dizygotic twins1, and familial aggregation (sibling risk ratio, λs = 29)2.   Since 2008, the field 
of SLE genetics has been transformed by GWA3–8 and independent replication studies9,10.  
However, while the pace of discovery has been unprecedented, providing a richer 
understanding of lupus genetic etiology, these findings were driven by modestly-sized GWA 
studies, utilizing 1,800 European patients3,4 and slightly fewer Asian cases5,6; they therefore 
had limited power to detect loci with relatively low odds ratios and/or minor allele 
frequencies11.  The size of our study, coupled with a meta-analysis and replication study, has 
greatly increased the power to detect susceptibility loci.  
We genotyped 4,946 individuals with SLE and 1,286 healthy controls using the Illumina 
HumanOmni1-Quad BeadChip.  These data were combined with the genotypes of 5,727 
healthy controls taken from the University of Michigan Health and Retirement Study (HRS), 
genotyped using the Illumina HumanOmni2.5 BeadChip. Following quality control (QC) 
analyses, our data comprised 4,036 SLE cases and 6,959 controls (1,260 controls mainly 
from southern Europe genotyped using the Omni1-Quad chip and 5,699 controls from the 
HRS cohort).  The final SNP set comprised 644,674 markers that were present on both the 
Omni1-Quad and Omni2.5 chips (see Online Methods).  Four principal components were 
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used as covariates to correct for population structure12,13.  The genomic inflation factor14,15 
for our data, λ1000, was 1.02, with λGC = 1.16.   
Our analysis strategy is described in detail in Online Methods, and is shown schematically in 
Supplementary Fig. 1.  This GWAS identified 25 loci (Table 1 and Supplementary Fig. 2a) of 
genome-wide significance (P < 5 x 10–08). Three of these associations are novel in SLE: 
rs6740462 and rs3768792 on chromosome 2p14 and 2q34, respectively and rs7726414 on 
chromosome 5q31.1.   
To validate these findings, and to search for additional susceptibility loci, we carried out a 
meta-analysis of our GWAS results and those from an independent European SLE GWAS 
comprising 1,165 cases and 2,107 controls (the Hom et al.4 study).  Each of the 25 loci 
mapped in the original GWAS had genome-wide significant p-values in this meta-analysis 
(Supplementary Table 1), and are therefore considered to be associated with SLE.  We then 
designed a replication study, with inclusion based on the meta-analysis of the two GWA 
studies.  At loci with no published association in SLE, we adopted a threshold for inclusion of 
P < 2.5 x 10–05, while for loci with previously reported associations the threshold was set at P 
< 1 x 10–04 (see Online Methods for rationale).  The 33 SNPs with P-values meeting these 
criteria were genotyped in our replication study (Supplementary Table 2), using a custom 
panel that also included 53 ancestry informative markers (see Online Methods).  After 
applying QC measures, the replication data comprised 2,018 cases and 6,925 controls, none 
of which had been included in either GWAS (see Online Methods). 
Finally, we carried out a post-replication meta-analysis of the results of our GWAS, the Hom 
et al. study and the replication study for those 33 SNPs, again applying the standard 
measure of genome-wide significance.  The 18 SNPs (over and above the 25 already 
mapped) with P-values < 5 x 10–08 in this meta-analysis were also considered to be 
associated with SLE (Table 1 and Supplementary Fig. 2b).  In addition to the three novel loci 
mapped in the GWAS, seven further variants, at loci hitherto not showing genome-wide 
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significant association in SLE, were mapped in the overall meta-analysis: rs564799 
(3q25.33), rs3794060 (11q13.4), rs10774625 (12q14.1), rs4902562 (14q24.1), rs9652601 
(7q32.1), rs2286672 (17p13.2) and rs887369 (Xp21.2).  The heritability explained by these 
43 validated susceptibility alleles is 19.3% [95% C.I. 14.1–25.5%], where the total heritability 
of lupus is estimated to be 66%16. This is a large increase on the 8.7% [5.33–12.96%] 
reported by So et al.17 in 2011 using the same measure. 
We imputed both the main GWAS and Hom et al. data to the density of the 1000 Genomes 
(1KG) study18 and re-analyzed the data (see Online Methods).  While no additional loci were 
identified, we did obtain stronger evidence in support of some loci, for example the signal at 
the SPRED2 locus, at which the most associated 1KG variant, rs268134, was strongly 
replicated.  In addition, the imputation enabled us to fine map associated loci and to 
determine whether multiple signals were present (Supplementary Tables 3a and 3b).  We 
identified multiple independent association signals at the TNFSF4, STAT4 and IRF5 loci, as 
well as five independently associated SNPs at the MHC (see below).  
Given that the SNP with the smallest P-value is not necessarily the true causal variant, we 
considered SNPs from the most associated to a defined cut-off as potentially causal in our 
subsequent analyses.  Specifically, guided by previous work on functional annotation19 (see 
Online Methods), the cut-off was defined as a Bayes Factor against the most significantly 
associated SNP equal to 0.34.  Any SNPs in this set that were missense variants were 
considered more likely candidates than the most associated SNP.  The results are 
summarized in Supplementary Tables 3c and 4, listing candidate causal missense variants 
in PTPN22, FCGR2A, NCF2, TNFAIP3, WDFY4, IRF7, ITGAM and TYK2.   
MHC polymorphisms, including SNPs and classical human leukocyte antigen (HLA) alleles, 
have consistently been observed to be associated with SLE20.  We imputed HLA alleles21 in 
both the main GWAS and Hom et al. data, and incorporated them into our analysis of 1KG 
imputed data across the MHC (see Online Methods).  Of the five MHC SNPs we find to be 
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independently associated with SLE (Supplementary Tables 3a and 3b), the class III SNP in 
SLC44A4 (rs74290525) is the only association signal that is clearly independent of any HLA 
alleles. We find that rs74290525 is significantly associated not only when conditioning on 
each of the HLA genes separately, but even when conditioning on all 199 HLA alleles (see 
Supplementary Tables 5a–e), and is not in linkage disequilibrium (LD) with any HLA alleles 
(R2 < 0.1 with each HLA allele).  We find that the best model for association includes the 
HLA class I alleles B*08:01, B*18:01, the class II alleles DQB1*02:01, DRB3*02:00 and 
DQA*01:02, and the class III SNP rs74290525, consistent with previous findings suggesting 
multiple SLE associations at the MHC20 (Supplementary Tables 6a and 6b).  LD between the 
five MHC SNPs and HLA alleles on known SLE risk haplotypes can be seen in 
Supplementary Table 6c.  
In order to highlight potential causal genes at the susceptibility loci, the associated SNPs at 
each of the loci were tested for correlation with cis-acting gene expression in ex vivo naïve 
CD4+ T cells, B cells, natural killer (NK) cells, and stimulated and resting monocytes22–24.  
Figure 1 displays a heat map across cell types, showing genes exhibiting significant 
differential expression in relation to the SLE associated alleles.  We calculated Regulatory 
Trait Concordance (RTC) scores25 (see Supplementary Figs. 3a and b) to test the 
relationship between eQTLs driven by disease-associated alleles, and other, potentially 
stronger eQTLs, which we identified at each locus.  The cis eQTLs were distributed across 
all cell types tested, some being common to all cell types, such as UBE2L3 and UHRF1BP1, 
while others are more cell specific: BLK in B cells and JAZF1 in T cells.  In general 
directionality was consistent, although not in all cases: for example ABHD6 showed reduced 
expression in monocytes and elevated expression in lymphocytes. 
We note that some caution must be used when inferring causality, as the RTC score has a 
uniform distribution and so setting an RTC score threshold of 0.9 for example, sets the type I 
error rate to be 0.1.  Furthermore, some low RTC scores were found in genes (e.g. UBE2L3) 
where the associated allele resides in a region with strong LD, and the haplotype bearing the 
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associated allele shows robust evidence of functional effects on gene expression26.  We 
suggest that the gene expression analyses provide some support for likely causal genes, but 
we note that proof of true causality through altered gene expression will only be elucidated 
by additional experimentation. 
We then integrated the results of these eQTL analyses and the coding variant analysis with 
an in silico survey of murine phenotype data resulting from targeting gene knockouts of 
genes within the associated SLE loci (Table 2).  At some loci, these lines of evidence point 
to one likely causal gene: examples include IFIH1, LYST, WDFY4 and BANK1.  In other 
instances, we found evidence that supports the role of multiple genes as candidates at a 
given locus; for example, ABHD6 (an enzyme involved in the endocannabinoid pathway) and 
PXK (a lymphocyte protein kinase)3 both exhibit correlation of their expression with the 
associated SNP.  Similarly, TCF7 (coding a T cell transcription factor), implicated by the 
rs7726414 association, has been associated with type 1 diabetes27; however, we show that 
SKP1 (which encodes a protein involved in the regulation of ubiquitination), within the same 
LD block exhibits a strong cis eQTL in monocytes and NK cells.  rs9652601 resides within 
CLEC16A, a gene previously reported in association studies in other autoimmune 
diseases28; we present evidence suggesting that SOCS1 (Suppressor of Cytokine Signaling 
1) is a causal gene at this locus in SLE rather than CLEC16A.  Our analyses have the 
advantage of including cis eQTLs based on ex vivo cells, rather than cell line data alone.  
Nevertheless, we acknowledge the restricted range and activation states of immune cell 
types available for eQTL analyses and the limited number of murine and other functional 
studies performed on genes at the loci.   
The 10 previously unmapped SLE loci (shown in bold type in Table 1 and Supplementary 
Table 3a) encompass genes of diverse function.  Those of note include IKZF2 (Helios), 
which represents the third member of the Ikaros transcription factor family to be associated 
with SLE (in addition to IKZF1 and IKZF3).  The association signal in the phospholipase D2 
(PLD2) is a missense variant (R172C), which may alter the function of the enzyme that plays 
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a role in leukocyte migration and apoptosis.  The importance of IL12, a cytokine that plays a 
critical role in the generation of γ-interferon from Th1 T cells and NK cells, is highlighted by 
the association with IL12A (Table 1), and the suggestive associations at IL12B and the locus 
encoding the IL12 receptor, IL12RB2 (Supplementary Table 2). 
In view of the sexual dimorphism of SLE, the novel X chromosome association revealed by 
rs887369 is of note.  We suggest that the gene CXorf21 is likely to be etiological.  While the 
function of this gene is unknown, it is among a limited set of genes that largely escape X-
inactivation29.  Sex chromosome dosage has been implicated in the genetic risk of SLE30.  
We observed an elevated prevalence of Klinefelter’s syndrome31 in male cases in our GWAS 
compared with the general population (see Online Methods) strengthening the sex 
chromosome dosage hypothesis.  The only other gene close to rs887369 (Table 2) is GK 
(glycerol kinase) which does not escape X-inactivation, supporting CXorf21 as a candidate 
gene. 
Five other genes (TNIP1, IKZF1, ETS1, WDFY4 and ARID5B) that we mapped are novel in 
European SLE, but had been previously shown to be associated with SLE in Chinese 
subjects5,6.  SLE is more prevalent in non-European populations – our data suggest that 
locus heterogeneity among common genetic variants is unlikely to explain this differential 
prevalence.  
We present all of our principal findings in Fig. 2.  This figure indicates ten likely missense 
coding variants that contribute to SLE risk; these occur largely in genes encoding kinases 
and other enzymes.  It was noted that 16 of the genes shown are transcription factors, an 
enrichment above the nine expected (P = 2.3 x 10–05, χ2 test).  We studied the distribution of 
the expression of these transcription factors in the ex vivo immune cell types examined for 
eQTLs; we found no evidence of skewed expression in any cell type.  Our results suggest 
that an important facet in future exploration of SLE pathogenesis will be detailed scrutiny of 
trans eQTLs and regulatory expression networks in multiple immune cells.   
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Data access. Summary statistics from the GWAS will be released by deposition in 
ImmunoBase. All 1KG imputed summary statistics will also be available at 
http://insidegen.com/insidegen-LUPUS-data.html . 
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Figure legends 
Figure 1  Heat map for cis-acting gene expression RTC scores from ex vivo cells.  The heat 
map includes all genes with evidence of cis-regulatory (+/– 1Mb) action by SLE associated 
SNPs in at least one cell type. The color represents a signed-RTC-score: a positive score 
indicates that the associated allele in the GWAS is positively correlated with gene 
expression; a negative score indicates that the associated allele in the GWAS is negatively 
correlated with gene expression.  We set the RTC score to zero if the P-value for association 
was > 0.001.  Colors represent the RTC-scores as follows: blue, RTC < –0.9 (GWAS risk 
allele reduces expression); green, RTC < –0.5 (GWAS risk allele reduces expression); 
yellow –0.5 < RTC < 0.5; orange, RTC > 0.5 (GWAS risk allele increases expression); red, 
RTC > 0.9 (GWAS risk allele increases expression).  A white block indicates that data were 
not available for this cell type (see Supplementary Figure 4 for results on lymphoblastoid cell 
lines), either because the probe data failed QC or the probe was not present in the 
experiment platform.  Clustering was performed on cell types, including only genes with data 
observed for all cell types (i.e., missing data did not inform cell clustering). Genes were 
clustered using all available data across cells (missing data were not included when 
determining distance between pairs of genes if eQTL results were not observed for one of 
the pairs).  
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Figure 2  Summary of functional role of likely causal genes in SLE and other autoimmune 
diseases.  The concentric rings in the figure show several layers of evidence to support the 
functional annotation of likely causal genes for SLE listed in Table 2.  The genes are 
illustrated clockwise in chromosomal order with the grey arcs delineating those loci for which 
several genes are implicated.  Inner Ring 1 - the gene’s functional category, taken from 
Ingenuity Pathway Analysis; Middle Ring 2 - the presence of a cis-acting eQTL (Figure 1) 
and/or coding variant and Innermost Ring 3 - the number of autoimmune diseases 
(excluding SLE) in Immunobase - Type 1 diabetes (T1D), Celiac disease (CEL), Multiple 
Sclerosis (MS), Crohn’s Disease (CRO), Primary Billiary Cirrhosis (PBC), Psoriasis (PSO), 
Rheumatoid Arthritis (RA), Ulcerative Colitis (UC), Ankylosing Spondylitis (AS), Autoimmune 
Thyroid Disease (ATD), Juvenile Idiopathic Arthritis (JIA), Alopecia Areata (AA), 
Inflammatory Bowel Disease (IBD), Narcolepsy (NAR), Primary Sclerosing Cholangitis 
(PSC), Sjögren's Syndrome (SJO), Systemic Scleroderma (SSc), Vitiligo (VIT) - previously 
reported to be associated with the gene. 
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Table 1: Allelic associations at SLE susceptibility loci following meta–analysis with replication study 
GWAS Hom et al. GWAS Replication study Post–replication study meta–analysis 
SNP Chr Position (b37) Locusc P–value Odds Ratio P–value 
Odds 
Ratio P–value 
Odds 
Ratio P–value 
Odds 
Ratio 95% CI 
rs2476601 1 114,377,568 PTPN22 8.34E–13 1.39 9.06E–04 1.32 6.00E–15 1.54 1.10E–28 1.43 1.34 – 1.53 
rs1801274 1 161,479,745 FCGR2A 6.05E–11 1.21 1.78E–02 1.13 8.38E–03 1.10 1.04E–12 1.16 1.11 – 1.21 
rs704840 1 173,226,195 TNFSF4 1.65E–13 1.26 7.65E–05 1.25 2.32E–04 1.15 3.12E–19 1.22 1.17 – 1.27 
rs17849501a 1 183,542,323 SMG7  NCF2 1.63E–59 2.24 3.96E–05 1.58 2.84E–30 2.08 3.45E–88 2.10 1.95 – 2.26 
rs3024505 1 206,939,904 IL10 2.55E–03 1.12 3.99E–07 1.42 4.00E–03 1.15 4.64E–09 1.17 1.11 – 1.24 
rs9782955 1 236,039,877 LYST 5.58E–04 1.12 3.93E–06 1.33 1.38E–03 1.15 1.25E–09 1.16 1.11 – 1.22 
rs6740462a 2 65,667,272 SPRED2 2.31E–08 1.20 9.55E–02 1.11 4.91E–01 0.97 2.67E–05 1.10 1.05 – 1.16 
rs2111485 2 163,110,536 IFIH1 3.44E–06 1.15 2.97E–03 1.17 6.52E–05 1.16 1.27E–11 1.15 1.11 – 1.20 
rs11889341a 2 191,943,742 STAT4 1.17E–65 1.75 3.70E–13 1.54 2.16E–48 1.79 5.59E–122 1.73 1.65 – 1.81 
rs3768792 2 213,871,709 IKZF2 2.35E–08 1.26 5.49E–03 1.22 7.12E–05 1.22 1.21E–13 1.24 1.17 – 1.31 
rs9311676 3 58,470,351 ABHD6  PXK 5.37E–06 1.14 7.58E–02 1.10 1.45E–10 1.27 3.06E–14 1.17 1.13 – 1.22 
rs564799 3 159,728,987 IL12A 1.15E–06 1.15 2.83E–01 1.06 1.78E–04 1.15 1.54E–09 1.14 1.09 – 1.18 
rs10028805 4 102,737,250 BANK1 4.50E–10 1.21 4.68E–01 1.04 9.84E–11 1.28 4.31E–17 1.20 1.15 – 1.25 
rs7726414 5 133,431,834 TCF7  SKP1 9.17E–10 1.46 2.88E–01 1.14 3.97E–08 1.56 4.44E–16 1.45 1.32 – 1.58 
rs10036748 5 150,458,146 TNIP1 2.83E–18 1.32 3.36E–07 1.35 2.53E–24 1.50 1.27E–45 1.38 1.32 – 1.45 
rs2431697 5 159,879,978 MIR146A 3.23E–14 1.25 2.22E–03 1.18 4.16E–14 1.32 8.01E–28 1.26 1.21 – 1.31 
rs1270942 6 31,918,860 MHC class IIId 1.70E–101 2.52 6.15E–13 1.75 7.43E–60 2.23 2.25E–165 2.28 2.15 – 2.42 
rs9462027 6 34,797,241 UHRF1BP1 1.80E–05 1.14 1.47E–01 1.09 2.42E–04 1.15 7.55E–09 1.14 1.09 – 1.19 
rs6568431 6 106,588,806 PRDM1  ATG5 4.33E–12 1.22 2.29E–03 1.17 No Data No Data 5.04E–14 1.21 1.15 – 1.27 
rs6932056a 6 138,242,437 TNFAIP3 1.23E–16 1.82 8.08E–03 1.47 1.20E–14 1.99 1.97E–31 1.83 1.65 – 2.02 
rs849142 7 28,185,891 JAZF1 3.49E–05 1.13 4.23E–04 1.20 2.04E–04 1.14 8.61E–11 1.14 1.10 – 1.19 
rs4917014 7 50,305,863 IKZF1 4.10E–05 1.14 3.25E–03 1.19 1.49E–09 1.27 6.39E–14 1.18 1.13 – 1.24 
rs10488631 7 128,594,183 IRF5 2.66E–44 1.79 4.50E–17 1.93 2.86E–52 2.12 9.37E–110 1.92 1.81 – 2.03 
rs2736340 8 11,343,973 BLK 2.14E–16 1.30 6.42E–05 1.27 No Data No Data 6.28E–20 1.29 1.22 – 1.37 
rs2663052a 10 50,069,395 WDFY4 1.59E–08 1.18 6.25E–02 1.10 No Data No Data 5.25E–09 1.16 1.10 – 1.22 
rs4948496 10 63,805,617 ARID5B 1.17E–06 1.15 5.76E–01 0.97 2.76E–08 1.22 1.04E–10 1.14 1.10 – 1.19 
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rs12802200a 11 566,936 IRF7 8.43E–09 1.24 2.03E–02 1.18 No Data No Data 8.81E–10 1.23 1.15 – 1.31 
rs2732549a 11 35,088,399 CD44 1.31E–10 1.21 1.51E–03 1.18 1.88E–13 1.31 1.20E–23 1.24 1.19 – 1.29 
rs3794060 11 71,187,679 DHCR7  NADSYN1 1.13E–04 1.13 8.18E–02 1.11 2.61E–23 1.47 1.32E–20 1.23 1.18 – 1.29 
rs7941765 11 128,499,000 ETS1  FLI1 9.82E–07 1.15 4.64E–03 1.17 1.55E–03 1.12 1.35E–10 1.14 1.10 – 1.19 
rs10774625 12 111,910,219 SH2B3 9.47E–08 1.17 4.32E–03 1.16 9.81E–02 1.06 4.09E–09 1.13 1.08 – 1.18 
rs1059312 12 129,278,864 SLC15A4 3.20E–06 1.14 3.97E–03 1.16 4.14E–07 1.20 1.48E–13 1.17 1.12 – 1.21 
rs4902562 14 68,731,458 RAD51B 4.85E–05 1.13 1.49E–02 1.14 5.78E–05 1.16 6.15E–10 1.14 1.09 – 1.19 
rs2289583a 15 75,311,036 CSK 9.35E–09 1.20 1.68E–02 1.14 2.12E–06 1.20 6.22E–15 1.19 1.14 – 1.24 
rs9652601a,b 16 11,174,365 CIITA  SOCS1 3.86E–07 1.17 4.00E–01 1.05 2.71E–15 1.36 7.42E–17 1.21 1.15 – 1.26 
rs34572943a,b 16 31,272,353 ITGAM 1.74E–47 1.78 1.90E–07 1.52 1.04E–24 1.68 3.39E–76 1.71 1.61 – 1.81 
rs11644034 16 85,972,612 IRF8 1.25E–15 1.34 9.81E–03 1.18 5.42E–04 1.16 9.58E–18 1.25 1.19 – 1.32 
rs2286672b 17 4,712,617 PLD2 5.81E–05 1.24 2.50E–02 1.24 2.35E–04 1.27 2.93E–09 1.25 1.16 – 1.35 
rs2941509 17 37,921,194 IKZF3 4.32E–06 1.41 2.34E–01 1.16 6.27E–04 1.35 7.98E–09 1.35 1.22 – 1.49 
rs2304256a 19 10,475,652 TYK2 2.34E–12 1.26 1.51E–02 1.16 No Data No Data 3.50E–13 1.24 1.17 – 1.31 
rs7444a,b 22 21,976,934 UBE2L3 1.30E–13 1.28 1.89E–01 1.09 3.51E–11 1.32 1.84E–22 1.27 1.21 – 1.33 
rs887369a X 30,577,846 CXorf21 9.25E–07 1.16 6.62E–02 1.23 4.55E–04 1.14 5.26E–10 1.15 1.10 – 1.21 
rs1734787a X 153,325,446 IRAK1  MECP2 2.83E–11 1.57 8.58E–04 1.52 9.54E–06 1.20 1.78E–15 1.31 1.22 – 1.40 
Novel SLE associations are shown in bold type. 
a Imputed data in the Hom et al study. IMPUTE info scores: rs17849501 (0.78), rs6740462 (1.00), rs11889341 (0.99), rs6932056 (0.94), rs2663052 (1.00), rs12802200 (0.90), rs2732549 (1.00), 
rs2289583 (0.99), rs9652601 (1.00), rs34572943 (0.90), rs2304256 (0.95), rs7444 (1.00), rs887369 (0.83), rs1734787 (0.95).  
b Imputed controls in the replication study. IMPUTE info scores: rs9652601(0.99), rs34572943 (0.91), rs2286672(0.88), rs7444 (0.99). 
c For rationale for candidate gene selection at the associated loci see Table 2 
d For more detailed analysis of MHC see text 
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Table 2: Candidate genes at SLE associated loci 
 Associated 
SNP Chr Genes within +/–200kb of SNP 
Genes within same 
LD block as SNPa 
Immune 
phenotype in 
murine modelb
Coding 
variant 
cis eQTLs with 
SNP 
Functional and/or fine 
mapping studies 
and Reference 
Likely causal 
genesc 
rs2476601 1 MAGI3, PHTF1, RSBN1, PTPN22, BCL2L15 AP4B1, DCLRE1B, HIPK1, OLFML3 RSBN1, PTPN22 PTPN22 PTPN22 PTPN22  32 PTPN22 
rs1801274 1 
MPZ, SDHC, C1orf192 
FCGR2A, HSPA6, FCGR3A 
FCGR2B, FCGR2C, FCGR3B, FCRLA 
FCGR2A 
FCGR2A
FCGR2B 
FCGR3B 
FCGR2A 
FCGR2B 
FCGR3B  
FCGR2A, FCGR2B 
FCGR2A
FCGR2B 
FCGR3B 
33
34 
35 
FCGR2A
FCGR2B 
FCGR3B 
rs704840 1 TNFSF4 TNFSF4 TNFSF4 TNFSF4 36 TNFSF4 
rs17849501 1 NMNAT2, SMG7, NCF2, ARPC5, RGL1 APOBEC4 SMG7, NCF2  NCF2 SMG7 NCF2 37 SMG7, NCF2 
rs3024505 1 
RASSF5, EIF2D, DYRK3 
MAPKAPK2, IL10, IL19, IL20 
IL24, FAIM3, PIGR, FCAMR 
IL10 
RASSF5
MAPKAPK2, IL10 
FAIM3, FCAMR 
 IL10 38 IL10 
rs9782955 1 LYST, NID1 LYST LYST  LYST LYST 39 LYST 
rs6740462 2 ACTR2, SPRED2 SPRED2   SPRED2 
rs2111485 2 DPP4, GCG, FAP, IFIH1, GCA, KCNH7 IFIH1 IFIH1 IFIH1 IFIH1 IFIH1 40 IFIH1 
rs11889341 2 GLS, STAT1, STAT4, MYO1B STAT4 STAT1, STAT4  STAT4 41 STAT4 
rs3768792 2 IKZF2 IKZF2 IKZF2  IKZF2 42 IKZF2 
rs9311676 3 ABHD6, RPP14, PXK, PDHB, KCTD6 ACOX2, FAM107A, FAM3D PXK, PDHB   ABHD6, PXK 
ABHD6 
PXK 
43 
44 ABHD6, PXK 
rs564799 3 SCHIP1, IL12A IL12A IL12A  IL12A   IL12A 
rs10028805 4 BANK1 BANK1 BANK1  BANK1 BANK1 45 BANK1 
rs7726414 5 C5orf15, VDAC1, TCF7, SKP1 TCF7, SKP1 TCF7   SKP1   TCF7, SKP1 
rs10036748 5 IRGM, ZNF300, GPX3, TNIP1, ANXA6 CCDC69, GM2A, SLC36A3 TNIP1 
TNIP1 
ANXA6  TNIP1 46 TNIP1 
rs2431697 5 C1QTNF2, C5orf54, SLU7, PTTG1, MIR146A, 3142 intergenic PTTG1  MIR146A 47 MIR146A 
rs1270942 6 MHCd        
rs9462027 6 C6orf106, SNRPC, UHRF1BP1 TAF11, ANKS1A UHRF1BP1   
UHRF1BP1, 
ANKS1A, C6orf106 UHRF1BP1 48 UHRF1BP1 
rs6568431 6 PRDM1 ATG5 intergenic 
PRDM1 
ATG5  
PRDM1 
ATG5 
49 
50 PRDM1, ATG5 
rs6932056 6 TNFAIP3 PERP TNFAIP3 
TNFAIP3
PERP TNFAIP3 TNFAIP3 51 TNFAIP3 
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rs849142 7 JAZF1, CREB5 JAZF1   JAZF1   JAZF1 
rs4917014 7 ZPBP, C7orf72, IKZF1  IKZF1 IKZF1  IKZF1 52 IKZF1 
rs10488631 7 CALU, OPN1SW, CCDC136, FLNC ATP6V1F, IRF5, TNPO3, TSPAN33 IRF5, TNPO3 IRF5  IRF5, TNPO3 IRF5 53 IRF5 
rs2736340 8 MTMR9, SLC35G5, C8orf12 FAM167A, BLK, GATA4 BLK   BLK, XKR6 BLK 54 BLK 
rs2663052 10 WDFY4, LRRC18, VSTM4 WDFY4  WDFY4 WDFY4 WDFY4 55 WDFY4 
rs4948496 10 ARID5B, RTKN2 ARID5B ARID5B    ARID5B 
rs12802200 11 
B4GALNT4, PKP3, SIGIRR, ANO9, PTDSS2
RNH1, HRAS, LRRC56, C11orf35, RASSF7 
PHRF1, IRF7, CDHR5, SCT, DRD4, DEAF1 
EPS8L2, TMEM80, TALDO1 
LRRC56, LMNTD2 
RASSF7, MIR210HG 
PHRF1, IRF7, CDHR5 
SIGIRR 
IRF7 IRF7 
IRF7, RNH1, HRAS, 
RASSF7, PHRF1, 
and, TMEM80 
IRF7 56 IRF7 
rs2732549 11 APIP, PDHX CD44, SLC1A2 upstream, CD44 CD44  CD44 57 CD44 
rs3794060 11 DHCR7, NADSYN1, KRTAP5 DHCR7, NADSYN1   DHCR7, NADSYN1   DHCR7, NADSYN1
rs7941765 11 ETS1, FLI1 CUX2 intergenic 
ETS1
FLI1  
ETS1
FLI1 
58
59 ETS1 FLI1 
rs10774625 12 FAM109A, SH2B3 ATXN2, BRAP SH2B3, ATXN2 SH2B3  SH2B3 60 SH2B3 
rs1059312 12 TMEM132C, SLC15A4, GLT1D1 SLC15A4 SLC15A4  SLC15A4   SLC15A4 
rs4902562 14 RAD51B RAD51B     RAD51B 
rs2289583 15 
LMAN1L, CPLX3, ULK3, SCAMP2
MPI, FAM219B, COX5A, RPP25 
SCAMP5, PPCDC, C15orf39 
SCAMP5, PPCDC   CSK, ULK3, MPI, FAM219B, C15orf39 CSK 61 CSK 
rs9652601 16 CIITA, DEXI, CLEC16A, RMI2, SOCS1 TNP2, PRM3, PRM2 CLEC16A 
CIITA 
SOCS1  SOCS1, RMI2 
CIITA 
SOCS1 
62 
63 CIITA, SOCS1 
rs34572943 16 
ZNF668, ZNF646, PRSS53, VKORC1, BCKDK KAT8
PRSS8, PRSS36, FUS, PYCARD 
C16orf98, TRIM72, PYDC1, ITGAM 
ITGAX, ITGAD, COX6A2, ZNF843, ARMC5 
ITGAM 
ITGAM
ITGAX 
ITGAD 
PYCARD 
ITGAM ITGAM, PYCARD ITGAM 64 ITGAM 
rs11644034 16 C16orf74, EMC8, COX4I1, IRF8 intergenic IRF8  IRF8 65 IRF8 
rs2286672 17 
ALOX15, PELP1, ARRB2, MED11, CXCL16
ZMYND15, TM4SF5, VMO1, GLTPD2 
PSMB6, PLD2, MINK1, CHRNE, C17orf107 
GP1BA, SLC25A11, RNF167, PFN1, ENO3 
SPAG7, CAMTA2, INCA1, KIF1C 
PLD2 
ALOX15
CXCL16 
INCA1 
KIF1C 
PLD2 
PLD2 RNF167    PLD2 
rs2941509 17 NEUROD2, PPP1R1B, STARD3, TCAP, PNMT PGAP3, ERBB2, MIEN1, GRB7, IKZF3, ZPBP2 
ERBB2, HER–2, C17orf37 
GRB7, IKZF3, ZNFN1A3 IKZF3  IKZF3 66 IKZF3 
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GSDMB, ORMDL3, LRRC3C, GSDMA ZBPB2, GSDMB 
rs2304256 19 
DNMT1, S1PR2, MRPL4, ICAM1, ICAM4 ICAM5 
ZGLP1, FDX1L, RAVER1, ICAM3, TYK2, CDC37 
PDE4A, KEAP1, S1PR5, ATG4D, KRI1 
TYK2 
DNMT1, S1PR2 
ICAM1, S1PR5 
TYK2 
TYK2 TYK2, ICAM3 TYK2 67 TYK2 
rs7444 22 HIC2, RIMBP3C, UBE2L3, YDJC, CCDC116SDF2L1, PPIL2, YPEL1, MAPK1 
UBE2L3
YDJC MAPK1  UBE2L3 UBE2L3 26 UBE2L3 
rs887369 X CXorf21, GK CXorf21     CXorf21 
rs1734787 X 
L1CAM, LCA10, AVPR2, ARHGAP4, NAA10 
RENBP, HCFC1, TMEM187, IRAK1, MECP2 
OPN1LW, TEX28P2, OPN1MW, TEX28P1 
OPN1MW2, TEX28, TKTL1 
ARHGAP4, NAA10 
RENBP, HCFC1 
TMEM187, IRAK1 
MIR718, MECP2 
IRAK1   IRAK1 MECP2 68 IRAK1, MECP2 
 
a The LD block is defined as SNPs showing a correlation (r2) of 0.75 with the associated SNP  
b The immune phenotype designation is taken from http://www.informatics.jax.org/phenotypes.shtml of genes within +/–200kb of associated SNP 
c The genes implicated at each locus as potentially causal at each locus 
d The MHC is not included due to extended LD and gene density at the locus 
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ONLINE METHODS 
Data: genome-wide association study (GWAS) 
We genotyped 4,946 SLE cases and 1,286 healthy controls using the Illumina 
HumanOmni1-Quad BeadChip (1,140,419 markers). The genotyped controls were mostly 
from southern Europe, matching our Spanish, Italian and Turkish cases with controls from 
the same countries. We also used data for 5,727 previously genotyped controls taken from 
the University of Michigan Health and Retirement Study (HRS). These subjects were 
genotyped using the Illumina Human2.5M Beadchip (2,443,179 markers).   
The clinical features of our GWAS cohort were documented on the basis of standard ACR 
classification criteria.  The experiment was designed to avoid batch effects to the greatest 
extent possible.  All DNA samples were sent to the laboratory at King’s College London, UK, 
where the integrity of the DNA was checked.  The GWAS samples were then genotyped at a 
single laboratory.  All data analysis was carried out in the laboratory at King’s College. 
Genotyping for the GWAS was carried out using 82 plates, processed in 13 batches.  
Duplicate samples taken from HapMap Phase 3 were added to each plate to check 
genotyping quality.  Case-control status and country of recruitment were randomized across 
plates as far as possible, in order to avoid artifactual differences in genotyping between 
plates affecting association statistics. 
Our final dataset comprised genotyping of 644,674 SNPs for 4,036 SLE cases and 6,959 
controls (1,260 controls of mainly southern European ancestry and 5,699 from the HRS).  
Data: Hom et al. study 
We analyzed data from a previous genome-wide association study of SLE (the Hom et al. 
study), which comprised 1,165 cases following our QC analysis (see Supplementary Text).  
We used a further 2,107 previously genotyped controls from the NIH CGEMS study, which 
were genotyped using the Illumina HumanHap550 chip.  Owing to the lower density of 
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genotyping, in some cases data imputed to the density of the 1000 Genomes (1KG) study 
were used in the analysis of the Hom et al. study and the subsequent meta-analysis. 
Imputed data are identified in tables.  
Data: replication study 
A cohort of 2,310 cases not included in any previous genetic study of SLE was genotyped 
using a custom array.  The largest group of samples was from the UK, followed by cohorts 
from France, the USA, Germany and Canada.  
The control data for the replication study comprised 3,672 subjects from the HRS cohort 
(independent of those used in the GWAS), 3,102 subjects from a study of melanoma and 
1,202 subjects from a study of blood clotting. These control data were genotyped using the 
Illumina 2.5M chip.  Following QC procedures (Supplementary Text), the final control dataset 
comprised 6,925 individuals: 3,668 from the HRS, 2,889 from the melanoma study and 368 
from the blood clotting study.  The final case dataset consisted of 2,018 samples. 
In some cases, SNPs identified by our GWAS as genome-wide significant were not present 
in the replication control data (owing to absent genotyping in one of the three control sets 
following QC), and so genotypes for those SNPs were imputed (see below). Again, we 
identify these SNPs in our results tables. 
Ethical approval 
The UK subjects with SLE in the study were recruited with the study having obtained ethical 
approval from the London Ethics Committee (MREC/98/2/06 and 06/MRE02/9).  Individuals 
were invited into the study and given information sheets as well as verbal explanations of 
what the research entailed.  For those individuals willing to participate informed written 
consent was obtained.  The recruitment in continental Europe and Canada were subject to 
local review and ethical approval.  Copies of the relevant supporting documentation were 
sent to the investigators at King’s College at the commencement of the study. 
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Quality control  
Initial QC analysis of the genotype data was carried out in accordance with Illumina’s 
Technical Note on Infinium Genotyping Data.  In silico QC checks were carried out of: 
• Individual missingness  (3% threshold)  
• SNP missingness (3% threshold) 
• Identity-by-descent (IBD, 0.125 threshold) 
• Population structure  
• Minor allele frequency (MAF, 0.002 threshold) 
• Autosomal heterozygosity 
• X chromosome heterozygosity 
• Y chromosome calling and homozygosity  
• Hardy-Weinberg equilibrium (control data only) 
IBD analysis included checks both within and across cohorts; no subject in the main GWAS 
or Hom et al. study is related to any other subject in either cohort.  We calculated principal 
components for the GWAS data using the EIGENSTRAT algorithm12, and derived the 
empirical genomic inflation factor13,69 for these data.  As noted by Price and colleagues14, the 
definition of genomic control means that λGC is proportional to sample size.  We therefore 
report λ1000, the inflation factor for an equivalent study of 1000 cases and 1000 controls15,70, 
in the main text, as well as λGC.   
For the replication cohort, population structure was estimated using 46 ancestry informative 
markers (following QC measures on these SNPs).  As described in Supplementary Text, we 
merged these data with HapMap data to help identify non-European samples. Again, 
principal components were calculated using the EIGENSTRAT algorithm.  120 subjects that 
clustered with the non-European HapMap populations were removed from the analysis.   
Klinefelter’s syndrome 
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During QC analysis, we identified subjects in our GWAS cohort with abnormal karyotypes, 
consistent with Klinefelter’s syndrome (47, XXY).  Three of the 365 male cases in our main 
GWAS have clinical and genetic data that confirm their status as Klinefelter’s sufferers 
(Supplementary Text).  Given that the prevalence of Klinefelter’s syndrome in the general 
population is estimated to be 0.1 – 0.2%31, this estimate suggests an approximately four- to 
eight-fold increase in prevalence compared with 46, XY males, consistent with Klinefelter’s 
males and 46, XX females having a similar risk of developing SLE.   
Analysis: association 
All case-control analysis was carried out using the SNPTEST71,72 algorithm; we use a 
standard threshold of P = 5 x 10–8 for reporting genome-wide significance throughout.  The 
inverse variance method was used for meta-analysis.  All markers were fully genotyped in 
the main GWAS (i.e, no imputation was carried out).  The imputation carried out for the Hom 
et al. and replication studies, and fine mapping imputation, are described below. 
For all SNPs at which we report a novel association with SLE, we compared allele 
frequencies in the main GWAS controls with those in publically available control cohorts 
(1KG European samples18, Wellcome Trust Case Control Consortium (WTCCC) 
genotypes73, TwinsUK samples, HapMap CEU population data, and sample genotypes from 
the Knight laboratory expression data23). We tested for a statistically significant (α = 0.01) 
difference in allele frequency between our GWAS and the public controls, using a 1 degree 
of freedom χ2 test of allele frequencies.  One SNP failed this test (rs1439112, MGAT5) and 
was removed from further analysis.  In three further cases, the difference in allele frequency 
strengthened our observed association.  These data are presented in Supplementary Table 
7. 
Annotation of results 
Gene names listed in results tables were identified by overlaying GWAS results onto the 
UCSC Genome Browser. We adopted a threshold based on linkage disequilibrium: for each 
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SNP, we noted the set of markers with R2 > 0.75 with respect to the SNP of interest (Table 
2).   
Post hoc QC  
Checks carried out following case-control analysis included examination of plots of raw 
genotype intensity; this was of particular relevance given the increase in the numbers of 
relatively rare variants due to the higher density of genotyping (as with imputation, genotype 
calling is by definition more difficult for rarer variants). We checked that the intensity plots 
showed clusters of genotypes (i.e., homozygotes or heterozygotes) that were compact and 
well discriminated.  This check was also carried out with stratification by QC group.  Plots of 
intensity were examined for each associated SNP, and for all of the SNPs in the replication 
study.   
Analysis: replication study chip design  
We selected SNPs for the replication study based on the results of the meta-analysis of the 
two GWA studies.  At loci with no known association in SLE, we adopted a threshold of P = 
2.5 x 10–05, while for loci with previously reported associations the threshold was set at P = 1 
x 10–04.  This followed the methodology used in Box 1 of the WTCCC study of seven 
common diseases73.  This declared SNPs as associated if the posterior odds of association 
were greater than 10.  In that study, the assumption was made that 10 detectable genes 
were present, so the prior odds of a true association would be in the order of 100,000:1, 
assuming 1,000,000 independent regions in the genome. Based on the autoimmune 
genetics literature, we have assumed that there are likely to be as many as 500 genes 
associated with SLE. We have required posterior odds in favour of a SNP being associated 
to be >1 (as opposed to >10, which would be advisable if declaring an association rather 
than choosing SNPs for replication).  This gives a P-value threshold of 2.5 x 10–05.   For 
SNPs at loci with previously published SLE associations, we have reduced our threshold for 
inclusion in the replication study to P = 1 x 10–04.  This is because a priori we believe these 
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SNPs are more likely to be at susceptibility loci than those with no evidence of association, 
increasing the prior odds by at least a factor of 4. 
Analysis: 1000 Genomes (1KG) imputation 
For imputation, both the main GWAS and the Hom et al. data were pre-phased using the 
SHAPEIT algorithm74, and then imputed to the density of the 1KG study using IMPUTE71,72 
v2.2.3. Only markers with an IMPUTE INFO score > 0.7 were used in analysis.  For SNPs 
identified in our GWAS as genome-wide significant at which data were absent in the 
replication study controls, we imputed over a +/– 1Mb region around the SNP of interest.  
1KG data were used both to fine map loci and to determine whether multiple signals were 
present.  For this analysis, we carried out a meta-analysis of 1KG imputed GWAS and Hom 
et al. data. Association testing was performed on the 1KG data within a 1 Mb window of the 
reported SNP. For the MHC, we included the complete 8 Mb region (26–34 Mb) in our 
analysis. To scan for further independent signals, association tests were performed including 
the genotype data for the most highly associated SNP as a covariate.  If secondary signals 
were found to be associated by this analysis (with a P-value threshold of 5 x 10–08) and odds 
ratios were consistent across the single marker and conditional analyses, the secondary 
signals were reported as independent associations. 
In order to address the problem that the most associated (lead SNP, marker with the lowest 
p-value) variant is not necessarily the best candidate as the true causal variant, we 
considered markers from the most associated down to a defined cut-off. The cut-off was 
defined as a Bayes Factor (BF) against the most associated SNP equal to 0.34. This was 
derived from assuming a prior odds of causality for a non-synonymous SNP equal to 3, 
taken from an empirical analysis of GWAS annotation19,75. Any SNPs above this BF cut-off 
that were missense variants were declared as more likely candidates than the most 
associated SNP: assuming that the prior odds of a missense SNP (being causal) against a 
non-missense SNP to be equal to 3, any missense SNP with a BF > 0.34 will have a 
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posterior odds > 1 and will therefore have a higher posterior probability than the most 
associated marker (if the most associated marker is non-missense). Therefore we searched 
for functional variants within a set of markers where inclusion in this set required a maximum 
Bayes factor (BF) > 0.34 between the marker and the most associated SNP in the 1KG 
imputed data. We considered any marker that had a BF > 0.34 with respect to the most 
associated marker, and noted whether any had functional effects. We calculated an 
approximate BF following Wakefield76, using a prior distribution on effect size (odds ratio) 
that was proportional to MAF (as rare variants are believed to have large effects, while 
common variants are believed to exert small effects). The BF threshold implies that we 
believe associations with functional variants, such as missense variants, three times more 
(say) than intergenic variants that do not correlate with gene expression. We then calculated 
posterior model probabilities following Maller et al.77, but with prior odds of 3 between 
missense SNPs and non-missense SNPs; Maller et al. use a uniform prior on all model 
probabilities (all SNPs are considered to have equal weights a priori, and therefore the prior 
odds are 1).  We present these results in Supplementary Table 4 where we also, separately, 
display SNPs with a BF > 0.1 (as a strict threshold of 0.34 does not reflect the uncertainty in 
prior odds of causality and BF estimates).  We also calculated the BF between SNPs 
presented in Table 1 and the SNPs listed in Supplementary Table 3a and declared that the 
marker for association had changed if the BF was greater than 10 (equal to “strong” 
evidence on the Jeffreys’ scale78). These SNPs are annotated in Supplementary Table 3a. 
Analysis: the MHC and HLA alleles 
 
We included imputed HLA alleles in analysis of the MHC, allowing us to determine the most 
likely model of association within this region. HLA imputation was performed using HLA*IMP 
V221 using genotyped SNP data. To determine the best model for association within the HLA 
alleles alone we ran forward stepwise regression. We then tested the five SNPs listed in 
Supplementary Tables 6a–c for association, conditional on the HLA alleles. To test whether 
each of the five SNPs was independent of the HLA alleles (rather than just the alleles in the 
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best HLA model), we carried out a test conditional on all alleles (i.e., the HLA alleles were 
used as covariates) in each HLA gene, and for all HLA alleles over all genes. We used a 
significance threshold at each stage of the stepwise regression of P = 5 x 10–05, which is a 
Bonferroni adjustment for 204 tests (199 HLA alleles and 5 SNPs), with a familywise Type I 
error rate of 0.01.   
Analysis: gene expression data 
Gene expression data were obtained from three sources: firstly, we obtained data from 
Fairfax et al.22,23 and unpublished data from Fairfax and Knight for NK cells, naïve 
monocytes, monocytes stimulated by LPS (harvested after 2 hours and 24 hours), IFN and B 
cells. Secondly, we interrogated the Genevar database for LCL eQTL results, taking results 
from the MuTHER resource79. The CD4 (CD4 T cells) and CD14 (CD14/16 Monocytes) data 
were obtained from a previous study of gene expression in immune related cells24.  An 
adjustment was made for multiple testing using a Bonferroni correction, by counting the 
number of tests across all loci for genes within +/–1MB of the SLE associated SNP.  With a 
familywise test size of 0.01, the P-value threshold was 1.41 x 10–05. 
To test whether observed associations between SNPs and expression levels of cis-acting 
genes were purely due to chance, we calculated the RTC score25 for all SNP-gene eQTL 
results displayed in the heat map (Figure 1). This tests the null hypothesis that the GWAS 
associated SNP and the best eQTL (within a recombination hotspot) are tagging two 
separate effects, and the observed eQTL is purely due to the LD between the GWAS 
associated SNP and the “true” eQTL SNP. For our data, we were interested in the 
distribution of RTC scores, given that eQTL results were generated in multiple cell types. Not 
all eQTLs were consistently present across all these cells. We therefore plotted the RTC 
scores against the –log10 P-values supporting each cis eQTL in all cell types (Supplementary 
Figures 3a and 3b). Supplementary Figures 3a and 3b show that three genes were outlying: 
ITGAM in two cell types, and UBE2L3 and PLD2 in CD4 cells. However, we have strong a 
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priori evidence of a true causal effect on expression by polymorphisms around UBE2L326. 
For ITGAM, we note the low RTC scores in Figure 1, which includes all eQTL data for 
ITGAM given that the results are convincing for the eQTL in LPS stimulated monocytes (P = 
2.67 x 10–19 and RTC = 0.85).  We have removed the declaration of an eQTL for PLD2.  
Supplementary Figure 4 displays a heat map for these data using a t-statistic. 
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